An independent two-stage DCF analysis by a frontier AI model.
Revvity Inc. (formerly the life sciences arm of PerkinElmer) focuses heavily on selling to the pharmaceutical and biotech industries. Following its corporate restructuring, Revvity is shifting towards higher-margin reagents and software, de-emphasizing medical devices. While trailing revenue growth of 5.9% is solid and it generated $523 million in free cash flow, the company is still navigating its post-split strategy in a complex, competitive environment. The valuation suggests a moderate growth expectation.
Revvity is transitioning towards a higher-margin software and reagent model within life sciences.
High switching costs for embedded software and regulatory requirements create a solid moat.
Sentiment reflects uncertainty around the success of the post-split strategy despite long-term potential.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.